Sanaria Reports Positive Initial Safety Results for Groundbreaking PfSPZ-LARC2 Malaria Vaccine https://lnkd.in/gtP_4qme
About us
Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.
- Website
-
http://www.sanaria.com
External link for Sanaria Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Rockville, MD
- Type
- Privately Held
- Founded
- 2003
- Specialties
- Biotechnology and Vaccine Development
Locations
-
Primary
Get directions
9800 Medical Center Drive
SuiteA209
Rockville, MD 20850, US
Employees at Sanaria Inc.
-
Natasha KC
Manager, Research Laboratory Operations | Immunology & GMP Programs | Assay Development | Lab Compliance & Safety
-
Alexander Hoffman
Results-focused, Engaging Attorney | Expertise in Estate Planning, Strategy, Innovation & Partnership Building.
-
Jeremy Guth
Creative | Innovative | Solution Driven | Quality Leader
-
Anusha Gunasekera
Molecular Biologist, Regulatory Affairs Specialist, experienced in Clinical and Regulatory aspects of vaccine development, 20+ years of experience in…
Updates
-
Sanaria has been nominated for Best Biotech Award from the Vaccine Industry Excellence awards. Best Biotech Award recognizes companies or individuals who have demonstrated outstanding thought leadership in spearheading innovation within the biotech industry. This includes a commitment to providing platforms or technologies to develop vaccines for unmet medical needs. Please vote for Sanaria for Best Biotech Award! https://lnkd.in/e8ad9A_4
-
A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose. This innovative approach leverages decades of research and cutting-edge genetic engineering to combat one of the world’s deadliest diseases. https://lnkd.in/gGqwGn_B